Abstract
There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.
Original language | English |
---|---|
Pages (from-to) | 61-66 |
Number of pages | 6 |
Journal | Journal of Neuroimmunology |
Volume | 258 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - 2013 |
Keywords
- Anti-Kv1.4 antibody
- Myasthenia gravis
- Prognosis
- Thymoma
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology